---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115245"
form_type: "8-K"
ticker: "RIGL"
cik: "0001034842"
company_name: "RIGEL PHARMACEUTICALS INC"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T12:58:15.086478+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rigel Q3 2023: Total revenue $28.1M, net loss narrows to $5.7M; TAVALISSE sales record $24.5M

## Summary
- Q3 net loss $5.7M ($0.03/share) vs $19.0M ($0.11/share) in Q3 2022.
- Total revenue $28.1M: TAVALISSE $24.5M (+27% YoY), REZLIDHIA $2.7M, collaboration $1.0M.
- Cash and short-term investments $62.4M at Sep 30, 2023 vs $58.2M at Dec 31, 2022.
- Phase 1b R289 (IRAK1/4 inhibitor) in LR-MDS enrolling third cohort; preliminary data expected mid-2024.
- NECTAR trial fostamatinib arm ceased enrollment per DSMB recommendation; no safety concerns identified.

## SEC filing metadata
- accession: 0001104659-23-115245
- form_type: 8-K
- ticker: RIGL
- cik: 0001034842
- company_name: RIGEL PHARMACEUTICALS INC
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/tm2329984d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115245
- JSON: https://secwatch.observer/filing/0001104659-23-115245.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115245.txt

## Key facts
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported third quarter ended September 30, 2023 results: revenue $28.1 million, net income net loss of $5.7 million, EPS $0.03 per basic and diluted share.
  - Period: third quarter ended September 30, 2023
  - Revenue: $28.1 million
  - Net income: net loss of $5.7 million
  - EPS: $0.03 per basic and diluted share
  - Result: reported results
  source text: 2 tm2329984d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Rigel Reports Third Quarter 2023 Financial Results and Provides Business Update · Third quarter 2023 Total Revenue of $28.1 million which includes record TAVALISSE ® net product sales of $24.5 million and REZLIDHIA ® net product sales of $2.7 million · New data on olutasidenib in mIDH1 relapsed or
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm
- Earnings Releases
  RIGEL PHARMACEUTICALS INC reported nine months ended September 30, 2023 results: revenue $81.1 million, net income net loss of $25.8 million, EPS $0.15 per basic and diluted share.
  - Period: nine months ended September 30, 2023
  - Revenue: $81.1 million
  - Net income: net loss of $25.8 million
  - EPS: $0.15 per basic and diluted share
  - Result: reported results
  source text: compared to a net loss of $60.0 million, or $0.35 per basic and diluted share, for the same period of 2022. For the nine months ended September 30, 2023, total revenues were $81.1 million, consisting of $68.1 million in TAVALISSE net product sales, $6.7 million in REZLIDHIA net product sales, $5.3 million in contract revenues from collaborations, and $1.0 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1034842/000110465923115245/0001104659-23-115245-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.